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Abstract
Background: The beneficial effect of aspirin after coronary surgery is established; however, a
recent study reported the inability of low doses (100 mg) to inhibit postoperative platelet function.
We conducted a double-blind randomised trial to establish the efficacy of low dose aspirin and to
compare it against medium dose aspirin.
Methods:  Patients undergoing coronary surgery were invited to participate and consenting
patients were randomised to 100 mg or 325 mg of aspirin daily for 5 days. Our primary outcome
was the difference in platelet aggregation (day 5 – baseline) using 1 µg/ml of collagen. Secondary
outcomes were differences in EC50 of collagen, ADP and epinephrine (assessed using the technique
of Born).
Results:  From September 2002 to April 2004, 72 patients were randomised; 3 patients
discontinued, leaving 35 and 34 in the low and medium dose aspirin arms respectively. The mean
aggregation (using 1.1 µg/ml of collagen) was reduced in both the medium and low dose aspirin
arms by 37% and 36% respectively. The baseline adjusted difference (low – medium) was 6% (95%
CI -3 to 14; p = 0.19). The directions of the results for the differences in EC50 (low – medium)
were consistent for collagen, ADP and epinephrine at -0.07 (-0.53 to 0.40), -0.08 (-0.28 to 0.11)
and -4.41 (-10.56 to 1.72) respectively, but none were statistically significant.
Conclusion: Contrary to recent findings, low dose aspirin is effective and medium dose aspirin did
not prove superior for inhibiting platelet aggregation after coronary surgery.
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Background
Normal platelet physiology cannot be assumed to prevail
in conditions of severe physiological stress such as major
surgery. However, the impact of antiplatelet therapy is
critical in the early postoperative period after coronary
surgery as it confers lower in-hospital mortality [1] and
morbidity and improves graft patency [2].
The motivation for the present study was a report that low
dose aspirin (100 mg) did not inhibit collagen-induced
platelet aggregation after cardiac surgery [3]. Moreover,
our systematic review and indirect comparison meta-anal-
ysis suggested that trials using medium dose aspirin regi-
mens (325 mg) after coronary surgery could have better
graft patency rates than trials using low dose aspirin (75 to
150 mg) [4]. The evidence from both these sources sug-
gests that equivalence cannot be assumed between the
two dosing regimens.
To evaluate the biological efficacy of low dose aspirin and
to compare it against a medium dose preparation, we con-
ducted a double-blind randomized trial of low against
medium dose aspirin after coronary artery bypass surgery.
Methods
Participants
We conducted a Local Research Ethics Committee
(Huntingdon Local Ethics Research Committee)
approved prospective randomised trial. All patients
undergoing elective primary coronary artery bypass sur-
gery were invited to participate, and informed consent
was obtained. We excluded patients if they did not stop
antiplatelet therapy a week prior to surgery, had contrain-
dications to aspirin or were on other medications that
interact with aspirin, if surgery was performed without
cardiopulmonary bypass, if platelet transfusion was
administered intra-operatively or within the first 24 hours
and if extubation was not achieved in the first 24 hours (to
ensure all patients had 5 full days of oral antiplatelet ther-
apy).
Intervention and randomisation
On the first postoperative morning, patients were ran-
domised to receive one of the following identically encap-
sulated treatments: aspirin 100 mg or aspirin 325 mg for
5 days. Randomisation was undertaken by pharmacy into
treatment allocation blocks of 6 and medications were
stored in numbered containers. Participants, researchers
and statisticians were blind to the treatment allocations.
All patients routinely received low molecular weight
heparin postoperatively.
Outcome measures
Our primary outcome measure was percentage aggrega-
tion on day 5 (2 hours after drug administration,)
expressed as percentage of baseline, using 1.1 µg/ml colla-
gen as an agonist. Assessment of platelet aggregation was
undertaken using the technique of Born [5]. Secondary
outcome measures were the effective concentrations of
Horm collagen, adenosine diphosphate (ADP) and epine-
phrine on day 5 required to produce 50% aggregation
(EC50) compared to baseline.
Laboratory methods
Venous blood (30 ml) was collected into 3.8% trisodium
citrate monovettes (Sarstedt) and gently inverted to
ensure mixing. Within 30 minutes of venepuncture, sam-
ples were centrifuged at 1000 r.p.m for 15 minutes to
obtain platelet rich plasma (PRP). Platelet poor plasma
(PPP) was prepared by centrifuging 1 ml of PRP at 6000
r.p.m. for 1 minute. Platelet aggregation was determined
turbidimetrically using the Platelet Aggregation Profiler®
PAP-4 (BioData Corporation, PA, USA), with baseline
optical density set with PPP. PRP samples (225 µl) were
pre-warmed to 37°C for 30 seconds before the addition of
agonist (25 µl), with the stir bar rate set at 1000 r.p.m. PRP
samples were stimulated for 4.5 minutes with freshly pre-
pared adenosine 5'-diphosphate (ADP, Sigma; final con-
centration range of 0.25–5.0 µmol/l), Horm collagen
(Axis-Shield Diagnostics; range 0.11–4.4 µg/ml) and
epinephrine (Sigma; range 0.125–5.0 µmol/l). Stock
saline solutions of epinephrine and ADP were stored at -
80°C, with appropriate precautions taken to prevent the
light-dependent degradation of epinephrine. Platelet
aggregometry readings for each agonist were converted to
EC50 using curve fit software. The EC50 represents the
concentration of agonist required to cause 50% of maxi-
mal aggregation.
Sample size
The original trial started as a three arm study (low dose
aspirin, medium dose aspirin and clopidogrel) intending
to recruit 108 patients with 36 participants in each arm.
We aimed to be able to detect a difference of 30% in post-
operative platelet aggregation at day 5, expressed as a per-
centage of pre-operative values between any two arms.
An interim analysis of 54 patients (18 in each arm) was
planned with the stopping criterion of a significant differ-
ence at 2% level. At that stage, there would be at least 90%
power to detect a difference of at least 1.5 standard devia-
tions, and the inferior arm would be terminated.
Statistical methods
Patients were grouped according to treatment allocation.
Categorical data are presented as frequency (%) and con-
tinuous data as mean with standard deviation (SD) or
median with interquartile range (IQR). Comparisons of
categorical data between groups were made using Fisher's
exact test or Pearson's Chi Squared test. Continuous dataBMC Medicine 2006, 4:12 http://www.biomedcentral.com/1741-7015/4/12
Page 3 of 6
(page number not for citation purposes)
were compared using Student's t-test or Wilcoxon rank
sum as appropriate. Primary outcome was compared
using regression analysis (ANCOVA) with robust standard
errors to adjust for baseline values of platelet aggregation
and EC50 concentrations. Analyses were performed using
Stata 8.2 (StataCorp, Texas, USA).
Results
From September 2002 to April 2004, patients were con-
secutively screened for eligibility and 200 participants
were invited to participate, of whom 116 consented. A fur-
ther 26 did not meet the inclusion criteria, leaving 90
patients suitable for randomization. At interim analysis,
after 54 were randomized (18 in each arm), and the clopi-
dogrel arm was terminated in accordance to pre-planned
criterion owing to concerns for participant safety [6].
Of the 90 patients, a total of 36 were randomized to
medium dose aspirin, 36 to low dose aspirin and 18 to
clopidogrel. One patient did not receive allocated medica-
tion and another withdrew consent to the study in the low
dose aspirin arm. One patient did not receive the allo-
cated medication and 2 were withdrawn (abdominal
pain, re-operation) in the medium dose aspirin arm. We
analyzed the results from 35 and 34 patients in the low
and medium dose arms respectively by intention-to-treat.
As the results for patients in the clopidogrel arm have
been published [6], we report the results of the patients in
the two aspirin arms.
Primary outcome
The patients were well matched for baseline characteristics
(Table 1). Mean platelet aggregation (using 1.1 µg/ml of
collagen) was reduced in both medium and low dose aspi-
rin arms by 37% and 36% respectively (table 2). The base-
line adjusted difference comparing low to medium dose
(low – medium dose) was 6% (95% CI -3 to 14; p = 0.19)
in favour of medium dose but not statistically significant.
Secondary outcomes
The directions of the results for the differences in EC50
concentrations were consistent for all three agonists in
favour of medium dose, although none were statistically
significant. The baseline adjusted EC50 concentrations
(low – medium dose) for collagen, ADP and epinephrine
were -0.07 µg/ml (-0.53 to 0.40), -0.08 µmol/l (-0.28 to
0.11) and -4.41 µmol/l (-10.56 to 1.72) respectively.
Discussion
The results of our study confirm that both aspirin doses
(325 mg and 100 mg) were effective in the inhibition of
platelet aggregation after cardiac surgery. The mean reduc-
tions by day 5 compared to baseline were 37% and 36%
for the medium and low dose aspirin regimens respec-
tively.
Efficacy of low dose regimen
Our results contradict the findings of the observational
study by Zimmerman [3], who reported that 100 mg of
aspirin was insufficient to inhibit platelet aggregation
after coronary surgery, with a mean aggregation of 103%
of the baseline value in his series. It is not possible to
determine why the results for low dose aspirin from our
centre in Cambridge were so different from those of Zim-
merman in Düsseldorf. The baseline characteristics of our
patients were comparable, and our laboratory methods
were similar. However, unmeasured differences can exist.
A potential difference could be in the genetic makeup
with respect to aspirin resistance. The prevalence of PlA2
polymorphism (linked to aspirin resistance) has been
estimated at 39% in patients with ischaemic heart disease
Table 1: Baseline characteristics of patients randomised to 
aspirin
Medium dose Low dose
Sample size 36 36
Mean age, years (SD) 66 (6) 66 (8)
Mean height, m (SD) 1.75 (0.08) 1.73 (0.07)
Mean weight, kg (SD) 83.1 (2.4) 85.3 (2.6)
Male sex, n (%) 33 (92) 33 (92)
Mean platelet count, × 109 (SD) 229 (59) 211 (66)
Diabetes, n (%) 4 (11) 10 (28)
Hypercholesterolaemia, n (%) 33 (92) 32 (89)
Hypertension, n (%) 21 (58) 24 (67)
Current smokers, n (%) 3 (8) 0 (0)
Median number of grafts, n (IQR) 4 (3 to 4) 3.5 (3 to 4)
Median bypass time, min (IQR) 73 (60 to 86) 70 (54 to 87)
Table 2: Effects of aspirin on collagen induced platelet aggregation and EC50 concentrations postoperatively (final – baseline)
Baseline (SD) Final (SD) Difference (95% CI) P value
Percentage aggregation (using 1.1 µg/ml collagen)
Medium dose 70 (28) 32 (15) -37 (-46 to -28) <0.001
Low dose 76 (21) 39 (21) -36 (-46 to -27) <0.001
Mean EC50 concentration (using 0.11 – 4.4 µg/ml collagen)
Medium dose 0.53 (0.58) 1.79 (0.91) 1.23 (0.95 to 1.52) <0.001
Low dose 0.48 (0.51) 1.69 (1.10) 1.20 (0.80 to 1.59) <0.001BMC Medicine 2006, 4:12 http://www.biomedcentral.com/1741-7015/4/12
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[7], and has greater potential to influence the results of
studies with smaller sample sizes. The total number of
participants in the observational series by Zimmerman
was 24.
Clinical implications
Throughout, we have used platelet aggregation as a surro-
gate for clinical outcome, as clinical efficacy cannot be
assumed without evidence of inhibition. Our previous
Trial flow diagram Figure 1
Trial flow diagram. Footnote: numbers that were analyzed were more than expected, taking into account patients who discontinued or 
did not receive allocated medication owing to intention-to-treat analysis.BMC Medicine 2006, 4:12 http://www.biomedcentral.com/1741-7015/4/12
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indirect comparison meta-analysis suggested that the effi-
cacy of low dose aspirin cannot be assumed to be equiva-
lent to superior results with medium dose regimens in the
preservation of graft patency [4]. In vitro, however,
medium dose aspirin did not prove superior in the inhibi-
tion of platelet aggregation. The upper limit of the 95%
confidence interval was 14% for the primary outcome
measure in favour of medium dose aspirin, and it is diffi-
cult on the limited information available to be certain if
this excludes a clinically meaningful or important differ-
ence. Unfortunately (as in most research) we have gener-
ated more questions rather than clarifying answers.
Further translational research evaluating (in part) the
effects of platelet aggregation on clinical outcomes would
be invaluable.
Standardization of platelet aggregation
A difficulty that we encountered in comparing our results
with those from other centres was the lack of standardiza-
tion in measuring platelet aggregation. The most common
method is to use a fixed concentration of agonist to com-
pare percentage aggregation to baseline. However, the
drawbacks of this technique is that some samples do not
aggregate with a low dose of agonist or aggregate com-
pletely when a high dose is selected. Moreover, as differ-
ent fixed concentrations are used, it is not possible to
compare the results between centres. A solution is to
report EC50s, the concentrations of agonist that produce
50% aggregation. In this way, it is possible to avoid the
arbitrary selection of a fixed dose of agonist and also to
allow results from different studies to be compared.
Conclusion
Low dose aspirin is effective and medium dose aspirin did
not prove superior as an inhibitor of platelet aggregation
in vitro after coronary surgery. Further studies are required
to compare clinical outcomes with platelet aggregation
results, and researchers should consider the use of EC50
to report the results of platelet inhibition to facilitate com-
parisons among different centres.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
EL conceived and designed the study, performed the sta-
tistical analysis and drafted the initial and final manu-
script; JC was involved in designing the study, performed
the aggregometry, coordinated the clinical trials and
approved the final manuscript; TR and AA were involved
in coordinating the clinical trials and data collection and
helped draft the initial manuscript; SK was involved in
designing the study and approved the final manuscript; LS
helped design the study, performed the statistical analyses
and approved the final manuscript; KS and SB performed
aggregometry, helped in data collection and approved the
final manuscript; HM was involved in coordinating the
clinical trials and approved the final manuscript; SL was
the overall study supervisor, who participated in the
design, conduct and management of the project and
approved the final manuscript.
Acknowledgements
This study was funded by Papworth Hospital NHS Trust and the Papworth 
Hospital Surgeons Research Fund. Dr Lim was also supported by the Med-
ical Research Council, UK. The authors gratefully acknowledge Emma Kadri 
and Elizabeth Bligh from the Hospital Pharmacy for their assistance, Pap-
worth Hospital Research and Development department for project man-
agement, and the nurses of the Surgical Unit in Papworth hospital. We 
especially acknowledge the contribution of the late Andrew Trull for 
project team assistance.
References
1. Mangano DT: Aspirin and mortality from coronary bypass sur-
gery.  N Engl J Med 2002, 347:1309-1317.
2. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T,
Doherty J, Read R, Chesler E, Sako Y: Saphenous vein graft pat-
ency 1 year after coronary artery bypass surgery and effects
of antiplatelet therapy. Results of a Veterans Administration
Cooperative Study.  Circulation 1989, 80:1190-1197.
3. Zimmermann N, Kienzle P, Weber AA, Winter J, Gams E, Schror K,
Hohlfeld T: Aspirin resistance after coronary artery bypass
grafting.  J Thorac Cardiovasc Surg 2001, 121:982-984.
4. Lim E, Ali Z, Ali A, Routledge T, Edmonds L, Altman DG, Large S:
Indirect comparison meta-analysis of aspirin therapy after
coronary surgery.  BMJ 2003, 327:1309.
5. Born GVR: Aggregation of blood platelets by adenosine
diphosphate and its reversal.  Nature 1962, 164:927-929.
6. Lim E, Cornelissen J, Routledge T, Kirtland S, Charman SC, Bellm S,
Munday H, Khan O, Masood I, Large S: Clopidogrel did not inhibit
platelet function early after coronary bypass surgery: A pro-
spective randomized trial.  J Thorac Cardiovasc Surg 2004,
128:432-435.
7. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC,
Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ: A polymor-
phism of a platelet glycoprotein receptor as an inherited risk
factor for coronary thrombosis.  N Engl J Med 1996,
334:1090-1094.
Table 3: Adjusted outcome measures comparing low to medium 
dose aspirin (low – medium)
Baseline adjusted difference (95% CI) P value
Change in percentage aggregation *
Collagen 1 µg/ml 6 (-3 to 14) 0.19
ADP 5 µmol/l 6 (0 to 13) 0.07
Epinephrine 10 µmol/l 3 (-5 to 11) 0.44
Change in EC50 concentration **
Collagen µg/ml -0.07 (-0.53 to 0.40) 0.77
ADP µmol/l -0.08 (-0.28 to 0.11) 0.40
Epinephrine µmol/l -4.41 (-10.56 to 1.72)
* Positive results favour greater treatment effect for medium dose 
aspirin
** Negative results favour greater treatment effect for medium dose 
aspirinPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medicine 2006, 4:12 http://www.biomedcentral.com/1741-7015/4/12
Page 6 of 6
(page number not for citation purposes)
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1741-7015/4/12/prepub